Inhibition of breast tumour growth with intravenously administered PRKCA siRNA-and PTEN tumour suppressor gene-loaded carbonate apatite nanoparticles

Nabilah Ibnat, Rowshan Ara Islam, Ezharul Hoque Chowdhury

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)


Gene therapy aims to silence an oncogene through RNA interference, or replace an ab-normal tumour suppressor via gene augmentation. In this study, we intended RNA interference for PRKCA oncogene and gene augmentation for PTEN tumour suppressor with a view to reduce tumour growth in a mouse model of breast cancer. Inorganic carbonate apatite nanoparticles (CA NPs) were utilized to deliver the synthetic siRNA and the purified gene-carrying plasmid DNA both in vitro and in vivo. Effects of PRKCA siRNA-and PTEN plasmid-loaded NPs on viability of MCF-7, MDA-MB-231 and 4T1 breast cancer cells were assessed by MTT assay. The cell viability data in MCF-7 cell line demonstrated that combined delivery of PRKCA specific siRNA and PTEN plasmid with CA NPs had an additive effect to significantly decrease cellular growth compared to individual treatments. In addition, we observed a similar pattern of cumulative influence for combined treatment in triple negative MDA-MB-231 breast cancer cell line. Upon treatment with PRKCA siRNA+PTEN plasmid-loaded NPs, a remarkable decrease in the phosphorylated form of AKT protein of PI3K/AKT pathway was observed in Western blot, indicative of diminished prolifer-ative signal. Moreover, in vivo study in MCF-7 xenograft breast cancer mouse model demonstrated that the rate of growth and final tumour volume were reduced significantly in the mouse group that received intravenous treatment of PRKCA siRNA+NPs, and PTEN plasmid+NPs. Our findings demonstrated that PRKCA siRNA and PTEN plasmid loaded into CA NPs attenuated breast tumour growth, suggesting their therapeutic potential in the treatment of breast cancer.

Original languageEnglish
Article number8133
Number of pages16
JournalApplied Sciences
Issue number17
Publication statusPublished - Sept 2021


  • Gene therapy
  • Inorganic nanoparticles
  • Nanotherapeutics
  • Oncogene
  • PTEN
  • RNAi
  • Tumour suppressor

Cite this